IgA nephropathy (IgAN) is one the most common primary glomerulonephritis in children and adolescents worldwide, with 20% of children developing end-stage kidney disease (ESKD) within 20 years of diagnosis. There is a need for treatment guidelines, especially for steroids in children with primary IgAN, since the STOP-IgA trial casts doubts on the use of steroids in adults with intermediate risk. Pediatricians are prone to prescribe steroids in addition to renin-angiotensin system blockade (RASB) when proteinuria is > 0.5 g/l, eGFR deteriorates < 70 ml/min/1.73 m2, or when a biopsy sample shows glomerular inflammation. Lack of randomized controlled trials (RCTs) in children with IgAN has led to an absence of consensus on the use of immunosuppressive agents in the treatment of progressive IgAN. This literature review evaluates the available evidence on steroid treatment in children with IgAN.

中文翻译：

---

IgA肾病患儿的类固醇治疗。

IgA肾病（IgAN）是全世界儿童和青少年中最常见的原发性肾小球肾炎，在诊断的20年内，有20％的儿童患上了终末期肾脏病（ESKD）。有必要制定治疗指南，尤其是对于患有原发性IgAN的儿童中的类固醇，因为STOP-IgA试验对中度风险的成年人使用类固醇产生了怀疑。当蛋白尿> 0.5 g / l，eGFR恶化<70 ml / min / 1.73 m2或活检样本显示肾小球炎症时，除肾素-血管紧张素系统阻滞剂（RASB）外，儿科医生还倾向于开激素。缺乏针对IgAN儿童的随机对照试验（RCT），导致在进展性IgAN的治疗中使用免疫抑制剂尚无共识。